Literature DB >> 27086233

Cognitive impairments in first-episode drug-naive and chronic medicated schizophrenia: MATRICS consensus cognitive battery in a Chinese Han population.

Jing Qin Wu1, Da Chun Chen2, Yun Long Tan2, Mei Hong Xiu2, Fu De Yang2, Jair C Soares3, Xiang Yang Zhang4.   

Abstract

Cognitive deficits are a core feature of schizophrenia and we examined the cognitive profile of first-episode and chronic schizophrenia in a Chinese Han population using the MATRICS Consensus Cognitive Battery (MCCB). We recruited 79 first-episode drug-naïve (FEDN) schizophrenia, 132 chronic medicated schizophrenia inpatients and 124 healthy controls. We assessed patient psychopathology using the Positive and Negative Syndrome Scale (PANSS). MCCB total score (p<0.01) and index scores of category fluency, trail making A, digital sequence, Hopkins Verbal Learning Test (HVLT), mazes, and Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT) were significantly higher in FEDN than in chronic patients (all p<0.05). FEDN exhibited relative weakness in continuous performance, whereas chronic patients exhibited relative weakness in mazes. Multiple regression analysis confirmed that in FEDN and chronic patients, total score and negative symptom of PANSS were independent contributors to MCCB total score, respectively. Our results not only demonstrate the applicability of the MCCB as a sensitive measure of cognitive impairment for schizophrenia patients in a Chinese Han population, but also suggest that the compromised cognition is present in the early stage of schizophrenia, some of which could be more severe in the chronic stage of illness.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cognition; First-episode drug-naïve patients; MCCB; Psychopathology; Schizophrenia

Mesh:

Year:  2016        PMID: 27086233     DOI: 10.1016/j.psychres.2016.02.042

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  11 in total

1.  The Relationship between Cognitive Functions and Psychopathological Symptoms in First Episode Psychosis and Chronic Schizophrenia.

Authors:  Katarzyna Rek-Owodziń; Ernest Tyburski; Piotr Plichta; Katarzyna Waszczuk; Maksymilian Bielecki; Krzysztof Wietrzyński; Piotr Podwalski; Krzysztof Rudkowski; Anna Michalczyk; Tomasz Grąźlewski; Leszek Sagan; Jolanta Kucharska-Mazur; Jerzy Samochowiec; Monika Mak
Journal:  J Clin Med       Date:  2022-05-06       Impact factor: 4.964

2.  Altered resting-state functional connectivity of the cerebellum in schizophrenia.

Authors:  Chuanjun Zhuo; Chunli Wang; Lina Wang; Xinyu Guo; Qingying Xu; Yanyan Liu; Jiajia Zhu
Journal:  Brain Imaging Behav       Date:  2018-04       Impact factor: 3.978

3.  Increased Plasma Level of Longevity Protein Klotho as a Potential Indicator of Cognitive Function Preservation in Patients With Schizophrenia.

Authors:  Jian-Wen Xiong; Jin-Qiong Zhan; Tao Luo; Hai-Bo Chen; Qi-Gen Wan; Yan Wang; Bo Wei; Yuan-Jian Yang
Journal:  Front Neurosci       Date:  2020-06-16       Impact factor: 4.677

4.  Meta-analysis of cognitive function in Chinese first-episode schizophrenia: MATRICS Consensus Cognitive Battery (MCCB) profile of impairment.

Authors:  Huijuan Zhang; Yao Wang; Yuliang Hu; Yikang Zhu; Tianhong Zhang; Jijun Wang; Ke Ma; Chuan Shi; Xin Yu; Chunbo Li
Journal:  Gen Psychiatr       Date:  2019-07-22

5.  Neurocognition and social cognition in remitted first-episode schizophrenia: correlation with VEGF serum levels.

Authors:  Yaqin Zhao; Wenhuan Xiao; Kuanyu Chen; Qiongqiong Zhan; Fei Ye; Xiaowei Tang; Xiaobin Zhang
Journal:  BMC Psychiatry       Date:  2019-12-16       Impact factor: 3.630

6.  The microRNA-195 - BDNF pathway and cognitive deficits in schizophrenia patients with minimal antipsychotic medication exposure.

Authors:  Shujuan Pan; Wei Feng; Yanli Li; Junchao Huang; Song Chen; Yimin Cui; Baopeng Tian; Shuping Tan; Zhiren Wang; Shangwu Yao; Joshua Chiappelli; Peter Kochunov; Shuo Chen; Fude Yang; Chiang-Shan R Li; Li Tian; Yunlong Tan; L Elliot Hong
Journal:  Transl Psychiatry       Date:  2021-02-08       Impact factor: 6.222

7.  The difference of social cognitive and neurocognitive performance between patients with schizophrenia at different stages and influencing factors.

Authors:  Shengyun Chen; Yaxi Liu; Dennis Liu; Guican Zhang; Xiaoli Wu
Journal:  Schizophr Res Cogn       Date:  2021-02-25

8.  Optimizing and Individualizing the Pharmacological Treatment of First-Episode Schizophrenic Patients: Study Protocol for a Multicenter Clinical Trial.

Authors:  Jingmei Xiao; Jing Huang; Yujun Long; Xiaoyi Wang; Ying Wang; Ye Yang; Gangrui Hei; Mengxi Sun; Jin Zhao; Li Li; Tiannan Shao; Weiyan Wang; Dongyu Kang; Chenchen Liu; Peng Xie; Yuyan Huang; Renrong Wu; Jingping Zhao
Journal:  Front Psychiatry       Date:  2021-02-25       Impact factor: 4.157

9.  Sex differences in association between cognitive impairment and clinical correlates in Chinese patients with first-episode drug-naïve schizophrenia.

Authors:  Na Zhao; Xiao Hong Wang; Chuan Yi Kang; Yue Zheng; Li Ying Yang; Tie Feng Guan; Yun Xia Bai; Ran Wei; Hunter C Hinman; Xiang Yang Zhang
Journal:  Ann Gen Psychiatry       Date:  2021-04-21       Impact factor: 3.455

Review 10.  Advancing study of cognitive impairments for antipsychotic-naïve psychosis comparing high-income versus low- and middle-income countries with a focus on urban China: Systematic review of cognition and study methodology.

Authors:  Lawrence H Yang; Bernalyn Ruiz; Amar D Mandavia; Margaux M Grivel; Liang Y Wong; Michael R Phillips; Matcheri S Keshavan; Huijun Li; Jeffrey A Lieberman; Ezra Susser; Larry J Seidman; William S Stone
Journal:  Schizophr Res       Date:  2020-04-05       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.